Access research Institute

Brooksville, Florida 34613

6 studies enrolling now · 14 studies all time

What they study most

Alzheimer's Disease, COPD, Chronic Idiopathic Urticaria, Crohn's Disease, End Stage Kidney Disease, End Stage Renal Disease (ESRD), Gout, Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Metabolic Dysfunction Associated Steatohepatitis (MASH), Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting — Recruiting now
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• A Study to Evaluate Solrikitug in Participants With COPD (ZION) — Recruiting now
• To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout — Completed
• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 — Completed
• Extension Study of ABP-671 in Participants With Gout — Stopped early
• A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD — Completed
• Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria — Completed
• A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease — Status unconfirmed